A Podcast Discussion on the Current Treatment Landscape for Renal Cell Carcinoma.
Philipp IvanyiJonas Paul WiegmannHendrik EggersViktor GrünwaldPublished in: Advances in therapy (2023)
During the last 15 years, tremendous efforts have been made in the medical treatment of metastatic renal cell carcinoma (mRCC). Immune-oncological (IO) combinations are the current standard of care in the first-line setting of mRCC. Here, the current phase 3 trials CM214 (nivolumab/ipilimumab vs. sunitinib), KN426 (axitinib/pembrolizumab vs. sunitinib), Javelin-ren-101 (axitinib/avelumab vs. sunitinib), CM9ER (cabozantinib/nivolumab vs. sunitinib), and CLEAR (lenvatinib/pembrolizumab vs. sunitinib) were discussed. In the mentioned phase 3 trials, primary and secondary endpoints were discussed. Strengths and weaknesses of each trial were reflected in terms of overall survival, progression-free survival, objective remission, health quality of life, and safety. Reflecting on the data, as well as the current ESMO guidelines, we discuss choosing the appropriate medical treatment for patients' individualized treatment journey and relay the strength and weaknesses of each combination-starting with the appropriate first-line therapy.
Keyphrases
- metastatic renal cell carcinoma
- renal cell carcinoma
- healthcare
- free survival
- public health
- mental health
- randomized controlled trial
- clinical trial
- palliative care
- machine learning
- newly diagnosed
- rheumatoid arthritis
- quality improvement
- electronic health record
- phase ii
- prognostic factors
- rectal cancer
- ejection fraction
- advanced non small cell lung cancer
- big data
- minimally invasive
- robot assisted
- radical prostatectomy
- disease activity